Carmen Dominguez-Brauer, Kelsie L. Thu, Jacqueline M. Mason, Heiko Blaser, Mark R. Bray...
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
Zachary W. Veitch, David W. Cescon, Trisha Denny, Lisa-Maria Yonemoto, Graham Fletcher...
Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent
Jacqueline M. Mason, Dan Chi-Chia Lin, Xin Wie, Yi Che, Yi Yao….